Vestibular SchwannomaNCT06163664
Role of ChatGPT in Vestibular Schwannoma Management
A study testing Use of chatGPT for 1 week in people with Vestibular Schwannoma, run by University of Southern California.
Trial summary
Previous studies have demonstrated that patients frequently undergo significant decision conflict regarding major medical decisions in otolaryngology. There lack validated tools available for decision support for patients. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Vestibular Schwannoma
- What is being tested?
- Use of chatGPT for 1 week
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2027to 30 Nov 2027
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 18 years or older
- Diagnosed with vestibular schwannoma
- Have access to internet-enabled device that is compatible with ChatGPT
Who cannot join
- < 18 years old
- patient without diagnosis of vestibular schwannoma
- patient does not have access to internet-enabled device
- patient who declines study participation
About this study
Previous studies have demonstrated that patients frequently undergo significant decision conflict regarding major medical decisions in otolaryngology. There lack validated tools available for decision support for patients. While limited evidence has demonstrated that clinical decision support tools can alleviate decision conflict for patients with diagnosis in otolaryngology, conversational language models were not employed in these studies and may provide additional benefit in this context. This study seeks to evaluate the efficacy of using ChatGPT, a conversational language model with basic clinical knowledge, in alleviating decision conflict for patients with new diagnosis in otolaryngology. For this pilot study, vestibular schwannoma, a benign tumor that develops on the vestibular nerve with known clinical equipoise, has been chosen for the initial study diagnosis. Efficacy will be evaluated by comparison of responses to the Decisional Conflict Scale (DCS) and Satisfaction with Decision (SWD) scores between a group given training in ChatGPT and a control group (no ChatGPT training).
- Conditions
- Vestibular Schwannoma
- Being tested
- Use of chatGPT for 1 week
- Medical subject headings
- Neuroma, Acoustic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Use of chatGPT for 1 weekBehavioural
Use of chatGPT for 1 week
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Intervention with 1 week use of ChatGPT Receives: Behavioral: Use of chatGPT for 1 week |
| Delayed control | Active comparator | No ChatGPT use for 1 week and intervention after 1 week Receives: Behavioral: Use of chatGPT for 1 week |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in scores of Decisional Conflict Scale after ChatGPT use
The Decisional Conflict Scale (DCS) measures 5 dimensions of decision making (feeling: uncertain, uninformed, unclear about values, unsupported; ineffective decision making). 15-item validated questionnaire. Score range 5-75 (higher score corresponding to higher levels of conflict in decision making)
Measured: baseline, 1 week follow up, 2 week follow up
Changes in scores of Satisfaction with Decision after ChatGPT use
The Satisfaction with Decision (SWD) scale measures satisfaction with health care decisions. 6-item validated questionnaire. Score range 5-30 (higher score corresponding to higher levels of satisfaction with decision)
Measured: baseline, 1 week follow up, 2 week follow up
Changes in scores for Knowledge on vestibular schwannoma management after ChatGPT use
4-item questionnaire (Likert scale) assessing participants' confidence in understanding the diagnosis and treatment options for vestibular schwannoma. Score range 5-20 (higher score corresponding to higher levels of confidence in understanding diagnosis and management of vestibular schwannoma)
Measured: baseline, 1 week follow up, 2 week follow up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2023
- Study start1 Jan 2027 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Nov 2027 (estimated)
Why it stopped: The study was witbdrawn due to funding and resource limitations.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vestibular SchwannomaStudies of the same condition, open and under way.
- More trials run by University of Southern CaliforniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Janet Choi, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06163664
- Sponsor's protocol ID
- UP-23-00541
- Status last verified
- Jan 2026
- First submitted
- 24 Oct 2023
- Last updated
- 13 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of ChatGPT in Vestibular Schwannoma Management
- ClinicalTrials.gov ID
- NCT06163664
- Acronym / sponsor ID
- UP-23-00541
- Conditions
- Vestibular Schwannoma
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: The study was witbdrawn due to funding and resource limitations.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Study start
- 1 Jan 2027 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Nov 2027 (estimated)
- First posted
- 11 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Previous studies have demonstrated that patients frequently undergo significant decision conflict regarding major medical decisions in otolaryngology. There lack validated tools available for decision support for patients. While limited evidence has demonstrated that clinical decision support tools can alleviate decision conflict for patients with diagnosis in otolaryngology, conversational language models were not employed in these studies and may provide additional benefit in this context. This study seeks to evaluate the efficacy of using ChatGPT, a conversational language model with basic clinical knowledge, in alleviating decision conflict for patients with new diagnosis in otolaryngology. For this pilot study, vestibular schwannoma, a benign tumor that develops on the vestibular nerve with known clinical equipoise, has been chosen for the initial study diagnosis. Efficacy will be evaluated by comparison of responses to the Decisional Conflict Scale (DCS) and Satisfaction with Decision (SWD) scores between a group given training in ChatGPT and a control group (no ChatGPT training).
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Use of chatGPT for 1 weekIntervention with 1 week use of ChatGPT |
| Delayed control | Active comparator | Behavioral: Use of chatGPT for 1 weekNo ChatGPT use for 1 week and intervention after 1 week |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 18 years or older
- Diagnosed with vestibular schwannoma
- Have access to internet-enabled device that is compatible with ChatGPT
Key exclusion criteria (4 listed)
- < 18 years old
- patient without diagnosis of vestibular schwannoma
- patient does not have access to internet-enabled device
- patient who declines study participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Use of chatGPT for 1 weekUse of chatGPT for 1 week | Behavioural | Delayed control, Intervention |
Primary outcome
Changes in scores of Decisional Conflict Scale after ChatGPT use
Time frame: baseline, 1 week follow up, 2 week follow up
The Decisional Conflict Scale (DCS) measures 5 dimensions of decision making (feeling: uncertain, uninformed, unclear about values, unsupported; ineffective decision making). 15-item validated questionnaire. Score range 5-75 (higher score corresponding to higher levels of conflict in decision making)
Changes in scores of Satisfaction with Decision after ChatGPT use
Time frame: baseline, 1 week follow up, 2 week follow up
The Satisfaction with Decision (SWD) scale measures satisfaction with health care decisions. 6-item validated questionnaire. Score range 5-30 (higher score corresponding to higher levels of satisfaction with decision)
Changes in scores for Knowledge on vestibular schwannoma management after ChatGPT use
Time frame: baseline, 1 week follow up, 2 week follow up
4-item questionnaire (Likert scale) assessing participants' confidence in understanding the diagnosis and treatment options for vestibular schwannoma. Score range 5-20 (higher score corresponding to higher levels of confidence in understanding diagnosis and management of vestibular schwannoma)
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Vestibular Schwannoma
Enrolling by invitationObservational study
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Vestibular Schwannoma
RecruitingPhase 1/2
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Vestibular Schwannoma
Not yet recruitingPhase 2
Selumetinib for NF2-Related Schwannomatosis
Neurofibromatosis Type 2, NF2
RecruitingPhase 2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Neurofibromatosis Type 2, Vestibular Schwannoma
RecruitingPhase 3
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
Vestibular Schwannoma, Facial Nerve Paralysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Use of chatGPT for 1 week in people with Vestibular Schwannoma, run by University of Southern California.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in scores of Decisional Conflict Scale after ChatGPT use (time frame: baseline, 1 week follow up, 2 week follow up). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.